Salvianolic Acid (SAA) Treatment of FSHDThe third most common type of muscular dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD), affects over 870,000 individuals worldwide by causing debilitating pain, muscle weakness, fatigue along with many other symptoms in their face, shoulders, upper arms and lower legs. Researchers at Nationwide Children’s Hospital created a treatment using Salvianolic Acid (SAA) as a drug therapy for neuromuscular disorders including FSHD. SAA, a natural compound found in the Salvia plant, has never been used for treating FSHD or any other neuromuscular disorder before. The compound inhibits protein methyltransferase (PRMT1), protects cells from double-homeobox gene 4 (DUX4) induced death and reduces the addition of methyl groups on the DUX4 protein. As a result, SAA functionally inhibits DUX4 toxicity making it useful for FSHD therapy.
|
Tech ID2021-005 College(None) Licensing ManagerInventorsCategories(None) |
